|Yescarta is the second gene therapy product approval in the U.S.|
The U.S. Food and Drug Administration today approved Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. Yescarta, a chimeric antigen receptor (CAR) T cell therapy, is the second gene therapy approved by the FDA and the first for certain types of non-Hodgkin lymphoma (NHL). Continue reading.
/////////FDA, CAR-T cell therapy, large B-cell lymphoma, fda 2017, Yescarta, axicabtagene ciloleucel,